Want to see TWST full AI Analyst Report?
Top Page
Twist Bioscience
(NASDAQ:TWST)
Select Model
Select Model
Rating:60Neutral
Price Target:
$122.00
▲(35.15% Upside)
Action:Reiterated
Date:08/19/26
The score is held back primarily by weak financial performance driven by persistent losses and significant cash burn, despite improving revenue and gross margins and a relatively solid balance sheet. Technicals are a major offset with strong upward trend and favorable momentum, while valuation remains challenged due to negative earnings. The latest earnings call and recent corporate events are supportive (raised guidance, path to EBITDA breakeven, and strengthened liquidity via an equity raise), but execution toward sustainable cash flow remains the key swing factor.
Positive Factors
Sustained Revenue Growth
Consistent growth across a long sequence of quarters indicates expanding customer adoption and commercial traction. Strong DSPS and therapeutics performance, together with raised FY2026 guidance, supports a durable growth trajectory over the next several quarters.
Negative Factors
Persistent Operating Losses
Despite improving revenue and gross margin, Twist remains materially unprofitable and has not demonstrated consistent operating leverage. Continued losses could require further capital support and delay the point at which growth translates into durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent growth across a long sequence of quarters indicates expanding customer adoption and commercial traction. Strong DSPS and therapeutics performance, together with raised FY2026 guidance, supports a durable growth trajectory over the next several quarters.
Read all positive factors
Twist Bioscience (TWST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.19B
Dividend YieldN/A
Average Volume (3M)1.79M
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue Growth19.19%
EPS Growth-53.86%
CountryUS
Employees979
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-2.22
Shares Outstanding65,832,420
10 Day Avg. Volume1,142,308
30 Day Avg. Volume1,792,237
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$109.88Price Target Upside21.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.1
Revenue Forecast (FY)$446.39M
Twist Bioscience Business Overview & Revenue Model
Company Description
Twist Bioscience Corporation (TWST) is a synthetic biology and life-sciences company that designs and manufactures synthetic DNA at scale. It serves customers across biotechnology, pharmaceutical research and development, academic and government l...
How the Company Makes Money
Twist Bioscience primarily generates revenue by selling synthetic biology research products and related services to life-science and applied-market customers. Key revenue streams include: (1) Synthetic DNA products: Sales of custom DNA constructs ...
Twist Bioscience Earnings Call Summary
Earnings Call Date:Aug 03, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Nov 13, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.Positive Updates
Record Quarterly Revenue and Consecutive Growth
Reported record revenue of $118.4 million in Q3 FY2026, up 23% year-over-year, marking the 14th consecutive quarter of revenue growth.
Negative Updates
Adjusted EBITDA Loss and Elevated Operating Expenses
Adjusted EBITDA loss of approximately $11.3 million in Q3 FY2026 driven by planned one-time investments; operating expenses (excluding cost of revenue) rose to $98.7 million from $81.4 million year-over-year, including ~$2 million in employee transition costs and other one-time items.
Read all updates
Q3-2026 Updates
Positive
Negative
Record Quarterly Revenue and Consecutive Growth
Reported record revenue of $118.4 million in Q3 FY2026, up 23% year-over-year, marking the 14th consecutive quarter of revenue growth.
Read all positive updates
Company Guidance
Twist raised fiscal 2026 revenue guidance to $456–457M (≈21% YoY) after reporting Q3 revenue of $118.4M (23% YoY) and now expects Q4 revenue of $123–124M (≈25% YoY), with sequential growth in both DSPS and NGS (NGS returning to >20% YoY growth); gross margin was 52.8% in Q3 (70% of incremental revenue flowed to gross margin) and the company expects FY26 gross margin above 52% with a longer‑term goal >60%; adjusted EBITDA was a ~$11.3M loss in Q3 but Twist targets adjusted EBITDA breakeven in Q4 FY26 and to maintain that commitment into FY27, finished Q3 with $166.8M in cash, and reiterated expectations for triple‑digit percent order growth for AI‑enabled discovery in FY26 (and again in FY27), while projecting organic revenue to more than double by 2031.Twist Bioscience Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
74
Positive
Cash Flow
36
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 431.80M | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M |
| Gross Profit | 224.38M | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M |
| EBITDA | -107.79M | -52.10M | -176.71M | -174.15M | -211.68M | -143.91M |
| Net Income | -136.72M | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M |
Balance Sheet | ||||||
| Total Assets | 672.44M | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M |
| Cash, Cash Equivalents and Short-Term Investments | 166.84M | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M |
| Total Debt | 93.59M | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M |
| Total Liabilities | 226.70M | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M |
| Stockholders Equity | 445.74M | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M |
Cash Flow | ||||||
| Free Cash Flow | -93.12M | -75.63M | -69.17M | -170.25M | -226.24M | -139.31M |
| Operating Cash Flow | -53.07M | -47.63M | -64.09M | -142.47M | -124.39M | -112.24M |
| Investing Cash Flow | -45.24M | -24.76M | -3.07M | 50.61M | -232.93M | 156.16M |
| Financing Cash Flow | 13.80M | 28.54M | 6.89M | 911.00K | 270.53M | 329.18M |
Twist Bioscience Technical Analysis
Positive
90.27
Price Trends
95.63
Positive
76.45
Positive
57.65
Positive
Market Momentum
8.76
Negative
58.24
Neutral
68.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Positive. The current price of 90.27 is below the 20-day moving average (MA) of 105.91, below the 50-day MA of 95.63, and above the 200-day MA of 57.65, indicating a bullish trend. The MACD of 8.76 indicates Negative momentum. The RSI at 58.24 is Neutral, neither overbought nor oversold. The STOCH value of 68.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TWST.
Twist Bioscience Risk Analysis
Twist Bioscience disclosed 61 risk factors in its most recent earnings report. Twist Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Twist Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $2.40B | 21.55 | 32.81% | ― | 34.41% | 90.73% | |
60 Neutral | $8.19B | -56.04 | -29.89% | ― | 19.19% | -53.86% | |
60 Neutral | $2.08B | -8.15 | -6.31% | ― | 11.19% | 50.58% | |
53 Neutral | $513.44M | -6.62 | -7.87% | ― | 6.83% | -69.59% | |
52 Neutral | $3.12B | -7.17 | -15.88% | ― | 23.07% | 24.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
38 Underperform | $291.73M | -2.55 | -32.59% | ― | -3.16% | 72.02% |
* Healthcare Sector Average
TWST
Twist Bioscience
116.10
88.52
320.96%
MYGN
Myriad Genetics
2.87
-2.64
-47.91%
NEO
NeoGenomics
15.90
9.59
151.98%
CDNA
CareDx
46.18
34.61
299.14%
FLGT
Fulgent Genetics
18.57
-3.00
-13.91%
GRAL
GRAIL Inc
70.89
39.47
125.62%
Twist Bioscience Corporate Events
Business Operations and Strategy
Twist Bioscience tapped to validate Anthropic AI proteins
Positive
Aug 19, 2026
On August 18, 2026, Anthropic announced results from a multi-arm protein design campaign against 15 targets using its Claude Opus 4.8 and Mythos Preview models. As part of this effort, Anthropic selected Twist Bioscience as an independent evaluato...
Business Operations and StrategyPrivate Placements and Financing
Twist Bioscience Completes Upsized Public Equity Offering
Positive
Aug 5, 2026
On August 4, 2026, Twist Bioscience entered into an underwriting agreement with Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities for a public offering of 3,125,000 shares of common stock at $96.00 per share, with underwrite...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.